T.O. is an accomplished first-chair trial lawyer and appellate advocate focused on complex patent litigation, with an emphasis on disputes involving life sciences innovations. He has more than two decades of experience representing leading pharmaceutical, biotech, medical device, and diagnostics companies in high-stakes matters before federal District Courts, the Patent Trial and Appeal Board, and the US Court of Appeals for the Federal Circuit.
T.O. leads teams in competitor litigation involving Hatch-Waxman and other patent disputes and provides strategic advice to pharmaceutical companies on how to leverage the existing statutory and legal framework to advance their commercial goals.
Nationally recognized for his advocacy, T.O. has been repeatedly shortlisted by LMG Life Sciences for “Hatch-Waxman Litigator of the Year” and “Appellate Litigator of the Year: Intellectual Property.” He is ranked among the top-performing litigators in Patexia’s ANDA Litigation Intelligence Report.
T.O. has successfully served as lead counsel in disputes regarding the following pharmaceutical products:
- Actoplus Met XR (pioglitazone/metformin)
- Adcirca (tadalafil)
- Aponvie (aprepitant)
- Auryxia (ferric citrate)
- Banzel (rufinamide)
- Brevibloc (esmolol)
- Cialis (tadalafil)
- Cinvanti (aprepitant)
- Daliresp (roflumilast)
- Daytrana (methylphenidate transdermal patch)
- Doryx (doxycycline)
- Epaned (enalapril)
- Esbriet (pirfenidone)
- Firvanq (vancomycin)
- Focalin (dexmethylphenidate)
- Gilenya (fingolimod)
- Injectafer (ferric carboxymaltose)
- Jublia (efinaconazole)
- Kerydin (tavaborole)
- Lescol XL (fluvastatin)
- Lidoderm (lidocaine transdermal patch)
- Lunesta (eszopiclone)
- Minivelle (estradiol transdermal patch)
- Oracea (doxycycline)
- Pomalyst (pomalidomide)
- Pradaxa (dabigatran)
- Reclast (zoledronic acid infusion)
- Revlimid (lenalidomide)
- Suboxone (buprenorphine/naloxone sublingual film)
- Trulance (plecanatide)
- Uloric (febuxostat)
- Ultiva (remifentanil for injection)
- Velcade (bortezomib)
- Viagra (sildenafil)
- Vivelle-Dot (estradiol transdermal patch)
- Zometa (zoledronic acid infusion)
* Work performed while at prior firm
News & Press
Mintz Continues Strategic Growth of Its Patent Litigation Team with San Francisco Partner and Litigator for Life Sciences Innovators
February 24, 2026
Mintz is pleased to welcome Tung-On (T.O.) Kong, who has joined the firm as a Member in its Intellectual Property Division. A nationally recognized life sciences patent strategist, T.O. brings more than two decades of trial and appellate experience representing pharmaceutical, biotechnology, medical device, and diagnostics companies in bet-the-company disputes.
T.O. is an accomplished first-chair trial lawyer and appellate advocate focused on complex patent litigation, with an emphasis on disputes involving life sciences innovations. He has more than two decades of experience representing leading pharmaceutical, biotech, medical device, and diagnostics companies in high-stakes matters before federal District Courts, the Patent Trial and Appeal Board, and the US Court of Appeals for the Federal Circuit.
Recognition & Awards
Finalist for “Hatch-Waxman Litigator of the Year” for LMG Life Sciences (2024, 2025)
Finalist for “Appellate Litigator of the Year: Intellectual Property” for LMG Life Sciences (2022)
Recognized by Patexia as one of the best performing ANDA attorneys overall in its ANDA Litigation Intelligence Report (2022)
T.O. is an accomplished first-chair trial lawyer and appellate advocate focused on complex patent litigation, with an emphasis on disputes involving life sciences innovations. He has more than two decades of experience representing leading pharmaceutical, biotech, medical device, and diagnostics companies in high-stakes matters before federal District Courts, the Patent Trial and Appeal Board, and the US Court of Appeals for the Federal Circuit.
Involvement
- Member, American Bar Association
- Member, Association of Business Trial Lawyers
- Member, Bar Association of San Francisco
Recent Insights
Mintz is pleased to welcome Tung-On (T.O.) Kong, who has joined the firm as a Member in its Intellectual Property Division. A nationally recognized life sciences patent strategist, T.O. brings more than two decades of trial and appellate experience representing pharmaceutical, biotechnology, medical device, and diagnostics companies in bet-the-company disputes.